Moderna (MRNA)
(Real Time Quote from BATS)
$107.34 USD
+4.19 (4.06%)
Updated Apr 23, 2024 11:10 AM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
MRNA 107.34 +4.19(4.06%)
Will MRNA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MRNA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRNA
Is First Trust NASDAQ-100 Equal Weighted ETF (QQEW) a Strong ETF Right Now?
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
MRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Moderna (MRNA) Stock Moves -0.58%: What You Should Know
Moderna (MRNA) Stock Moves -0.34%: What You Should Know
Other News for MRNA
Moderna, Pfizer/BioNTech set for UK court clash over Covid jab patents
IN BRIEF: Moderna to deliver 12.5 million Covid vaccines to Brazil
Moderna Options Trading: A Deep Dive into Market Sentiment
MRNA March 2025 Options Begin Trading
Moderna announces contract with Brazil to supply 12.5M COVID-19 vaccines